Carboplatin Adjuvant Chemotherapy for Malignant Oral Melanoma with Pulmonary Metastasis in Two Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2015
P. Fonghem1; K. Sajjaviriyakul2; P. Teewasutrakul2; C. Setthawongsin3; S. Nantavisai4; S. Techangamsuwan5; A. Rungsipipat5
1Diploma Student Veterinary Pathology Program, Veterinary Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand; 2Oncology Clinic Small Animal Teaching Hospital, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand; 3PhD Candidate Veterinary Pathobiology Program, Department of Veterinary Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand; 4Surgical Unit Small Animal Teaching Hospital, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand; 5Companion Animal Cancer Research Unit, Department of Veterinary Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand

Introduction

Oral melanoma is the most common malignant tumor in dogs accounting for 30–40%. Local disease or stage I can be curative with aggressive surgery, but almost affected dogs are clinical stage III/IV with poor prognosis due to pulmonary metastasis.

Objectives

To present oral melanoma with pulmonary metastasis in two dogs applying carboplatin chemotherapy and treatment follow up.

Methods

Case No. 1

A 15-year-old, male Poodle with a 2.5 cm in diameter mass at the upper lip, was diagnosis as malignant amelanotic melanoma with pulmonary metastasis. Carboplatin was used at a dosage 250 mg/m2 and given every 3 weeks for 8 treatments.

Case No. 2

A 9-year-old, castrated male, mixed breed presented with a 5 cm in diameter mass at upper lingual. The diagnosis was malignant melanoma with submandibular lymph node and pulmonary metastasis. Adjuvant chemotherapeutic protocol, carboplatin at a dosage of 250 mg/m2 and doxorubicin at a dosage of 60 mg/m2, alternating combination of a 3-week interval was given for 6 treatments.

Results

Recurrence of oral masses and evidence of drug toxicity were not observed in both dogs. They showed normal vital signs with appetite. Hematology, kidney, liver and cardiac function tests were within normal range. Median survival time was 246 (No. 1) and 146 days (No. 2).

Conclusions

Survival times of two dogs were longer than that of previous reports for dogs affected with stage IV oral malignant melanoma. Carboplatin adjuvant chemotherapy is a palliative treatment that can reduce burden and improve quality of life of melanoma affected dogs.

  

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

P. Fonghem
Veterinary Pathology Program
Faculty of Veterinary Science
Chulalongkorn University
Bangkok, Thailand


MAIN : Oncology : Carboplatin Adjuvant Chemotherapy
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27